doi: 10.3389/fsurg.2025.1618362 Received 25 April 2025 Accepted 28 August 2025 Published 15 September 2025 Volume 12 - 2025 Edited by Rafael De La Garza Ramos, Albert Einstein College of Medicine, United States Reviewed by Marica Eoli, IRCCS Carlo Besta Neurological Institute Foundation, Italy Hajnalka Rajnai, Semmelweis University, Hungary Zhenhua Li, Brigham and Women's Hospital and Harvard Medical School, United States Updates Copyright 2025 Guranda, Wach, Gresir, Braune, Kuzman and Nestler
Pozzi M, Mazhar F, Peeters GGAM, Vantaggiato C, Nobile M, Clementi E, et al
Votre chirurgien est en mesure dvaluer si la liposuccion 360 pourrait vous convenir et vous permettre dobtenir les rsultats escompts
doi: 10.3390/nu17020264 44 MiaoY.ChenY.XueF.LiuK.ZhuB.GaoJ.et al
This compound is intended strictly for use in controlled research environments and is not approved for human or veterinary use
Discovery of fevipiprant (NVP-QAW039), a potent and selective DP2 receptor antagonist for treatment of asthma
